KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Retained Earnings (2016 - 2025)

Eli Lilly (LLY) has disclosed Retained Earnings for 17 consecutive years, with $24.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 666.17% year-over-year to $24.5 billion, compared with a TTM value of $24.5 billion through Dec 2025, up 666.17%, and an annual FY2025 reading of $24.5 billion, up 666.17% over the prior year.
  • Retained Earnings was $24.5 billion for Q4 2025 at Eli Lilly, up from -$3.2 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $24.5 billion in Q4 2025 and bottomed at -$6.4 billion in Q1 2021.
  • Average Retained Earnings over 5 years is $1.7 billion, with a median of -$3.8 billion recorded in 2023.
  • The sharpest move saw Retained Earnings crashed 155.47% in 2021, then skyrocketed 666.17% in 2025.
  • Year by year, Retained Earnings stood at -$4.3 billion in 2021, then surged by 331.23% to $10.0 billion in 2022, then plummeted by 143.09% to -$4.3 billion in 2023, then grew by 0.12% to -$4.3 billion in 2024, then surged by 666.17% to $24.5 billion in 2025.
  • Business Quant data shows Retained Earnings for LLY at $24.5 billion in Q4 2025, -$3.2 billion in Q3 2025, and -$3.7 billion in Q2 2025.